David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Meta-analyse bevestigt hoge remissiepercentage na CAR T-celtherapie bij B-ALL
apr 2021 | Leukemie